Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998052574) VITAMIN D ANALOGUES AND THEIR NEURONAL EFFECTS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/052574 International Application No.: PCT/US1998/010480
Publication Date: 26.11.1998 International Filing Date: 21.05.1998
Chapter 2 Demand Filed: 13.11.1998
IPC:
A61K 31/59 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
59
Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
Applicants:
CEPHALON, INC. [US/US]; 145 Brandywine Parkway West Chester, PA 19380, US
LEO PHARMACEUTICAL PRODUCTS LTD. A/S [DK/DK]; Industriparken 55 DK-2750 Ballerup, DK
Inventors:
CARSWELL, Susan; US
DOBRZANSKI, Pawel; US
BINDERUP, Lise; DK
BJÖRKLING, Fredrik; SE
MILLER, Matthew, S.; US
Agent:
CREASON, Gary, L. ; Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110-2804, US
Priority Data:
09/082,76221.05.1998US
60/047,39122.05.1997US
Title (EN) VITAMIN D ANALOGUES AND THEIR NEURONAL EFFECTS
(FR) ANALOGUES DE VITAMINE D ET LEURS EFFETS SUR LES NEURONES
Abstract:
(EN) The present invention is directed, $i(inter alia), to methods of utilizing low calcemic vitamin D analogues. Particularly, the present invention is directed to using low calcemic vitamin D analogues to treat neurodegenerative diseases and disorders, to facilitate endogenous production of neurotrophic factors, to inhibit the degradation, dysfunction or loss of neural cells and/or to enhance the phenotype of neural cells or neuronal processes.
(FR) La présente invention a trait, entre autres, à des procédés d'utilisation d'analogues de vitamine D à faible teneur en calcium. En particulier, la présente invention a trait à l'utilisation d'analogues de vitamine D à faible teneur en calcium pour traiter des maladies et des troubles neurodégénératifs, pour faciliter la production endogène de facteurs neurotrophiques, pour inhiber la dégradation, le dysfonctionnement ou la perte de cellules nerveuses et/ou améliorer le phénotype de cellules nerveuses ou de processus neuronaux.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
NO19995683NZ501119MXPA/a/1999/010714KR1020010012770EP1011683JP2002513416
CA2290772AU1998076917